Liver Tumor Clinical Trial
Official title:
Prospective Single Arm Phase II Study of TACE Combined With Lenvatinib and MWA After Down-stage in the Treatment of Locally Advanced Large Hepatocellular Carcinoma
To explore the objective effectiveness and safety of TACE combined with Lenvatinib in the treatment of advanced liver cancer. After successful down-stage, radical microwave ablation was further performed.
Status | Recruiting |
Enrollment | 46 |
Est. completion date | November 2023 |
Est. primary completion date | January 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Patients aged 18-75 years with hepatocellular carcinoma have an expected survival of at least 3 months; - Number of tumors = 3; - Large hepatocellular carcinoma with tumor diameter = 7 cm; - Patients without inferior vena cava tumor thrombus, portal vein tumor thrombus and cholangiocarcinoma thrombus; - Although there is arteriovenous fistula or arterioportal fistula, it can be completely blocked; - Child Pugh grade A or B of liver function; ECoG physical fitness score < 2; - No bleeding tendency, normal coagulation function or coagulation dysfunction can be corrected after treatment; - Leukocyte count = 3.0 × 109/L; - Hemoglobin = 8.5g/dl; - Platelet count = 50 × 109/L; - The international normalized ratio of prothrombin time (INR) = 2.3 or prothrombin time (PT) does not exceed the upper limit of normal control for 3 seconds; - Serum creatinine was less than 1.5 times of the upper limit of normal; - Patients and / or family members agree to join the clinical trial and sign the informed consent form Exclusion Criteria: - Diffuse hepatocellular carcinoma; - Portal vein tumor thrombus; - Combined with tumor thrombus of hepatic vein and inferior vena cava; - Patients with lymph node metastasis and extrahepatic distant metastasis; - The liver function was classified as child Pugh C and could not be improved by liver protection treatment; - Arteriovenous fistula or arterioportal fistula with ineffective intervention; - Uncorrectable coagulation dysfunction and obvious hemogram abnormalities, with obvious bleeding tendency; - Intractable massive ascites; - ECoG physical fitness score > 2 points; - Combined with active infection, especially bile duct inflammation; - Serious heart, lung, kidney, brain and other important organ diseases; - Note: see attached table 1 for child Pugh classification of liver function; See attached table 2 for ECoG physical fitness score |
Country | Name | City | State |
---|---|---|---|
China | Sun Yat-sen University Cancer Center | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Sun Yat-sen University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Down stage rate | if the patient achieve any of these three criteria: ? the patient was downgraded from BCLC stage C to BCLC stage B (portal branch tumor thrombus was inactive, the focus was less than or equal to 7cm; or the focus did not invade the surrounding tissue after shrinking) or Milan standard (single tumor diameter was not more than 5cm or less than or equal to 3 tumors, and the maximum diameter was not more than 3cm, without vascular invasion). ? Liver function reaches child Pugh grade A or B; ? The patient is in good health and can tolerate ablation. | 4 months | |
Secondary | RFS | Recurrence free survival indicates the length of time after MWA for a cancer ends that the patient survives without any signs or symptoms of HCC | 3 years | |
Secondary | Objective response rate | Change of the tumor size according to the modified response evaluation criteria in solid tumors (mRECIST) [see attached table 3], the efficacy is defined as CR (complete remission), PR (partial remission), SD (stable) and PD (Progress) | 3 years | |
Secondary | Changes of liver and kidney function | Changes of liver and kidney function index from blood biochemistry compared to baseline | 3 years | |
Secondary | TACE frequency and ablation frequency | To access the times and frequency of TACE and ablation | 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04241887 -
Is Thoracic Paravertebral Block a Better Option Than Conscious Sedation for PRFA of Liver Tumors
|
N/A | |
Recruiting |
NCT04274868 -
Pediatric Hepatic Tumors
|
||
Completed |
NCT02985034 -
Safety Margin Assessment After RFA Using the Registration of Pre-ablation MRI and Post-ablation CT
|
N/A | |
Completed |
NCT02424955 -
Feasibility 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation
|
N/A | |
Recruiting |
NCT03579199 -
Practical Application of Indocyanine Green Camera in Laparoscopic Liver Surgery
|
N/A | |
Completed |
NCT02958592 -
Assessment of Hepatic Fibrosis by Shear Wave Elastography in Patients With Liver Malignancy: A Prospective Single-center Study
|
N/A | |
Completed |
NCT05370001 -
Endotracheal Tube Size Effect on the Carbon Dioxide Washout During Jet Ventilation
|
N/A | |
Recruiting |
NCT02203409 -
Laparoscopic Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy
|
||
Enrolling by invitation |
NCT03739164 -
Tampa Associating Microwave Liver Ablation With Portal Vein Ligation for Staged Hepatectomy (TAMLAPS)
|
||
Recruiting |
NCT05211388 -
Treat-and-resect Study of Echo Decorrelation Imaging-controlled Radiofrequency Ablation in Liver Tumors
|
N/A | |
Recruiting |
NCT05516394 -
National Polish Registry of Minimally Invasive Liver Surgery
|
||
Completed |
NCT02849015 -
Combination of Cryosurgery and NK Immunotherapy for Tumors in Transplanted Liver
|
Phase 1/Phase 2 | |
Completed |
NCT02018107 -
PET/CT-Assessment of Liver Tumor Ablation
|
N/A | |
Recruiting |
NCT01677728 -
Effect of Target Therapy on Patients Undergoing Synchronic Hepatectomy for Colorectal Liver Metastases
|
N/A | |
Recruiting |
NCT06060899 -
Intraoperative Blood Loss Under Standard Versus Low Pneumoperitoneum Pressure During Laparoscopic Liver Resection.
|
N/A | |
Completed |
NCT03783871 -
NeuWave HCC China Study
|
N/A | |
Enrolling by invitation |
NCT01812577 -
Paravertebral Block for Percutaneous Radiofrequency Ablation of Liver Lesions
|
||
Not yet recruiting |
NCT05161624 -
Accuracy Evaluation of Artificial Intelligence Assisted Liver Tumor Ablation Path Planning
|
||
Completed |
NCT02226666 -
Physiologic Assessment Following Gadoxetic Acid and Gadobenate Dimeglumine Administration
|
N/A | |
Recruiting |
NCT04812054 -
Dual Hypothermic Oxygenated Machine Perfusion in Liver Transplantation Using Allografts From Donors After Brain Death
|
N/A |